Chargement en cours...
Expanded use of rituximab in the management of non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemente...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886316/ https://ncbi.nlm.nih.gov/pubmed/20616906 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|